SchrödingerNASDAQ: SDGR

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported that on June 11, 2024, the company granted (i) a non-statutory stock option and (ii) restricted stock units (RSUs).

Schrodinger, Inc. reported a quarterly loss of $0.76 per share, matching the Zacks Consensus Estimate. This is compared to a loss of $0.38 per share in the same quarter last year.

Schrödinger is set to announce its financial results for the first quarter of 2024 on May 1, 2024, after the close of the financial markets.

While the top- and bottom-line numbers for Schrodinger, Inc. (SDGR) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for Schrodinger, Inc. (SDGR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Customers in the biopharma industry are cutting spending, creating a soft demand environment for Schrodinger's software and drug discovery services. Despite the recent share price spike, Schrodinger's valuation is still low when accounting for all of the company's assets (cash, equity, milestones, royalties, software business). While Schrodinger's stock should do well long-term, growth is likely to remain weak in the near term and losses will remain high while the company invests in its proprietary pipeline.

Schrödinger, Inc. (NASDAQ:SDGR ) Q3 2023 Results Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications Ramy Farid - President and Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies LLC Malcolm Hoffman - BMO Capital Markets Michael Ryskin - Bank of America Securities, Inc. Matthew Hewitt - Craig-Hallum Capital Group Joseph Catanzaro - Piper Sandler Chris Shibutani - Goldman Sachs & Co. Operator Welcome to Schrödinger's Conference Call to review Third Quarter 2023 Financial Results. My name is Eric and I will be your operator for today's call.

Schrödinger is a leading AI drug discovery company with a comprehensive platform used by researchers and scientists worldwide. The company's flagship product, Maestro, integrates various proprietary software tools for molecular modeling and simulation. SDGR has experienced significant growth and has established itself as the industry standard in the AI revolution in healthcare.